In the general news, Hillary Clinton’s collapse during the Sunday 9/11 ceremonies dominated news all week. Then, a week later, multiple ISIS-inspired attacks took place across the country. On the Jersey Shore, IED’s failed to explode during a running race. In New York City, one pressure-cooker bomb did explode, inuring dozens, while another one failed to detonate. Then, in a Minneapolis mall, a radical Islam man stabbed nine people. Meanwhile, Donald Trump continued to lead Hillary Clinton in the polls.
In healthcare business news, there was little news as Americans extended the Labor day holiday into a two-week event.
On the data front, Novavax (NVV) shares tanked 84% after its vaccine for RSV failed.
From the FDA, Aralez Pharmaceuticals (ARLZ) received approval for drug Yosprala to prevent gastric ulcers caused by aspirin. Also, a panel recommended that the strong warning labels on Pfizer’s (PFE) Chantix be removed.
And in other regulatory news, new NIH rules will prevent drug makers from keeping results of clinical trials private. The data is supposed to now be posted on clinicaltrials.gov.